AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30844881 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS stimulation
Number of subjects: 34
Study 27852935 — intervention group
Group type: EXPERIMENTAL
Intervention: RSLV-132
Number of subjects: 32
Study 25450303 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOM group
Number of subjects: 194
Study 25450303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 194
Study 24419419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 125
Study 24419419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 125
Study 24419419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Sunitinib
Number of subjects: 125
Study 22119182 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered brief intervention addressing alcohol misuse and violence
Number of subjects: 60
Study 20087310 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative dance program (12 weeks, 3 sessions of 90 minutes per week)
Number of subjects: 37
Study 17291851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group (breast-fed with mother on a low allergen diet or given an extensively hydrolyzed formula)
Number of subjects: 120
Study 17291851 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group
Number of subjects: 120
Study 17291851 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard advice)
Number of subjects: 120
Study 15475800 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg per day for 60 days
Number of subjects: 38
Study 15475800 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 38
Study 11762668 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 1 hour after acetaminophen ingestion
Number of subjects: 10
Study 11762668 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 2 hours after acetaminophen ingestion
Number of subjects: 10
Study 11762668 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 3 hours after acetaminophen ingestion
Number of subjects: 10
Study 11762668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activated charcoal)
Number of subjects: 10
Study 9248874 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 10
Study 9248874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8501274 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine/stannous fluoride rinse
Number of subjects: 102
Study 8501274 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 2963166 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (Met12‐(3‐28)‐eicosahexapeptide, 2 micrograms/min)
Number of subjects: 8
Study 2963166 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Ve)
Number of subjects: 8
Study 31738834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 127
Study 31738834 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 127
Study 31738834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (prednisone ≤0.25 mg/kg/day)
Number of subjects: 127
Study 31738834 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (prednisone ≤0.25 mg/kg/day)
Number of subjects: 127
Study 28438062 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation during pregnancy
Number of subjects: 388
Study 28438062 — intervention group
Group type: COMPARATOR
Intervention: Smoking during pregnancy
Number of subjects: 388
Study 27159069 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB with 10 mL lidocaine 1%
Number of subjects: 20
Study 25700845 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB with resistance training (RT-HMB)
Number of subjects: 48
Study 25700845 — intervention group
Group type: COMPARATOR
Intervention: No-training placebo (NT-PL)
Number of subjects: 48
Study 25700845 — intervention group
Group type: COMPARATOR
Intervention: HMB only (NT-HMB)
Number of subjects: 48
Study 25700845 — intervention group
Group type: COMPARATOR
Intervention: RT with placebo (RT-PL)
Number of subjects: 48
Study 25700845 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB with RT (RT-HMB)
Number of subjects: 48
Study 23866924 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine
Number of subjects: 120
Study 23866924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20602760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet
Number of subjects: 0
Study 20602760 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet in fed state
Number of subjects: 0
Study 20602760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg) and Paracetamol (500 mg) fixed-dose combination tablet given three times daily
Number of subjects: 0
Study 19034329 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg/day)
Number of subjects: 852
Study 16473325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring imagery modification
Number of subjects: 0
Study 16473325 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure
Number of subjects: 0
Study 16473325 — intervention group
Group type: COMPARATOR
Intervention: Minimal exposure, relaxation control
Number of subjects: 0
Study 15143854 — intervention group
Group type: EXPERIMENTAL
Intervention: Mold exposure
Number of subjects: 209
Study 10959067 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50-400 mg/day
Number of subjects: 117
Study 9497506 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 1200 mg/day
Number of subjects: 27
Study 9497506 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin 40-80 mg at night
Number of subjects: 27
Study 8396081 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg daily for 3 days)
Number of subjects: 118
Study 8396081 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin (dicloxacillin 12.5‐25 mg/kg daily for 7 days or flucloxacillin 250‐2000 mg/day for 7 days)
Number of subjects: 118
Study 8396081 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 118
Study 8396081 — intervention group
Group type: COMPARATOR
Intervention: Cloxacillin (dicloxacillin or flucloxacillin)
Number of subjects: 118
Study 8396081 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin and Cloxacillin (dicloxacillin or flucloxacillin)
Number of subjects: 118
Study 3774197 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 140
Study 3774197 — intervention group
Group type: COMPARATOR
Intervention: Control group (various operations on the digestive tract)
Number of subjects: 140
Study 29776444 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosonography (EBUS and EUS) without mediastinoscopy
Number of subjects: 360
Study 29776444 — intervention group
Group type: COMPARATOR
Intervention: Endosonography (EBUS and EUS) with mediastinoscopy
Number of subjects: 360
Study 26894424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation therapy (5 weekly sessions)
Number of subjects: 0
Study 26894424 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study 23830802 — intervention group
Group type: EXPERIMENTAL
Intervention: Small incision lenticule extraction (SMILE)
Number of subjects: 30
Study 23830802 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond laser-assisted laser in situ keratomileusis (femto-LASIK)
Number of subjects: 30
Study 21246186 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving counseling intervention (8 weekly sessions in groups of 8-10 adults)
Number of subjects: 420
Study 21246186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 420
Study 21246186 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving counseling intervention
Number of subjects: 420
Study 20626160 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring circumcision
Number of subjects: 724
Study 20626160 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical procedures
Number of subjects: 724
Study 18543479 — intervention group
Group type: EXPERIMENTAL
Intervention: YQHX (supplementing qi and activating blood circulation method)
Number of subjects: 76
Study 18543479 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medicinal treatment
Number of subjects: 76
Study 15968385 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS inhalation
Number of subjects: 6
Study 15968385 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation
Number of subjects: 6
Study 11495488 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized amikacin treatment
Number of subjects: 37
Study 11495488 — intervention group
Group type: EXPERIMENTAL
Intervention: Single urine assay for monitoring nebulized amikacin
Number of subjects: 37
Study 9565507 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 29
Study 9565507 — intervention group
Group type: EXPERIMENTAL
Intervention: MUGA
Number of subjects: 29
Study 9565507 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study 7755480 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 75 mg a day (n = 8)
Number of subjects: 13
Study 7755480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 13
Study 2472126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (100 to 200 mg/d)
Number of subjects: 10
Study 2472126 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 8180714 — intervention group
Group type: EXPERIMENTAL
Intervention: Health fair, health risk information, follow-up screening, and incentive program (five $100 cash prizes for reducing serum cholesterol levels by 20% or below 5.17 mmol/L)
Number of subjects: 63
Study 8180714 — intervention group
Group type: COMPARATOR
Intervention: Health fair, health risk information, and follow-up screening (no incentive program)
Number of subjects: 63
Study 762369 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine 6 mg daily
Number of subjects: 14
Study 762369 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotoxine 3 mg daily
Number of subjects: 14
Study 31291879 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative breathing exercises (deep breathing, cough, and incentive spirometer)
Number of subjects: 100
Study 31291879 — intervention group
Group type: COMPARATOR
Intervention: Hospital routine physiotherapy (control group)
Number of subjects: 100
Study 29037640 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement control exercises
Number of subjects: 32
Study 29037640 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Number of subjects: 32
Study 29037640 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Movement control and Stabilization)
Number of subjects: 32
Study 25886131 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety interventions (two arms)
Number of subjects: 36
Study 25886131 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 36
Study 24377218 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy of regulating qi circulation of fu-organ
Number of subjects: 75
Study 24377218 — intervention group
Group type: COMPARATOR
Intervention: Shengxue Tongbian Capsules
Number of subjects: 75
Study 20639765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 666
Study 20639765 — intervention group
Group type: COMPARATOR
Intervention: Double-bolus eptifibatide
Number of subjects: 666
Study 19139435 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 1 g/m2 over 24 hours with intrathecal injection and folinic acid rescue at 42 hours (MTX1 arm)
Number of subjects: 352
Study 19139435 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 3 g/m2 over 3 hours without intrathecal injection and folinic acid rescue at 24 hours (MTX3 arm)
Number of subjects: 352
Study 19139435 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate 1 g/m2 over 24 hours (MTX1 arm)
Number of subjects: 352
Study 19139435 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate 3 g/m2 over 3 hours (MTX3 arm)
Number of subjects: 352
Study 17703713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridges intervention (Standard Treatment plus Bridges)
Number of subjects: 18
Study 17703713 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment with Attention Control
Number of subjects: 18
Study 15073108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 09‐4889 (1-200 mg)
Number of subjects: 64
Study 15073108 — intervention group
Group type: COMPARATOR
Intervention: Ro 09‐4889 (20 mg)
Number of subjects: 64
Study 15073108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 09‐4889
Number of subjects: 64
Study 11455810 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 micrograms orally
Number of subjects: 0
Study 9603112 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 11
Study 9603112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7906814 — intervention group
Group type: EXPERIMENTAL
Intervention: Echo‐planar imaging (EPI)
Number of subjects: 11
Study 7906814 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound measurements
Number of subjects: 11
Study 3136639 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive enteral supplements
Number of subjects: 22
Study 3136639 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 22
Study 31841106 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (generic from Panacea)
Number of subjects: 56
Study 31841106 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (innovator from Astellas)
Number of subjects: 56
Study 31841106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 56
Study 31165950 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg)
Number of subjects: 80
Study 31165950 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 80
Study 28118938 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKA vaccine accelerated regimen
Number of subjects: 37
Study 28118938 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKA vaccine classic regimen
Number of subjects: 37
Study 28118938 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine classic regimen
Number of subjects: 37
Study 28118938 — intervention group
Group type: EXPERIMENTAL
Intervention: PIKA vaccine
Number of subjects: 37
Study 24834925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 or 10 mg/kg every 4 weeks)
Number of subjects: 163
Study 24834925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 24834925 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 163
Study 23399108 — intervention group
Group type: EXPERIMENTAL
Intervention: Gland-preserving surgery
Number of subjects: 40
Study 23399108 — intervention group
Group type: COMPARATOR
Intervention: Surgical excision of the entire gland
Number of subjects: 40
Study 21705958 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented group (LF)
Number of subjects: 473
Study 21705958 — intervention group
Group type: COMPARATOR
Intervention: Control formula group (CF)
Number of subjects: 473
Study 21705958 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed group (BF)
Number of subjects: 473
Study 20035630 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quality control program (QCP) for acupuncture trials
Number of subjects: 0
Study 20035630 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance and monitoring by appointed monitors
Number of subjects: 0
Study 20035630 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meetings for performance improvement
Number of subjects: 0
Study 16847400 — intervention group
Group type: COMPARATOR
Intervention: R‐/S‐bicalutamide/HP55S 150 mg
Number of subjects: 0
Study 16847400 — intervention group
Group type: COMPARATOR
Intervention: R‐bicalutamide/HP55S 150 mg
Number of subjects: 0
Study 16847400 — intervention group
Group type: COMPARATOR
Intervention: R‐bicalutamide/HP55S 450 mg
Number of subjects: 0
Study 16847400 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐bicalutamide/HP55S
Number of subjects: 0
Study 16847400 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐/S‐bicalutamide/HP55S
Number of subjects: 0
Study 16847400 — intervention group
Group type: EXPERIMENTAL
Intervention: R‐bicalutamide/HP55S and R‐/S‐bicalutamide/HP55S
Number of subjects: 0
Study 12490770 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg/day)
Number of subjects: 123
Study 12490770 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg/day)
Number of subjects: 123
Study 11571221 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourette's syndrome subjects
Number of subjects: 20
Study 11571221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9670800 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐exposure in vivo
Number of subjects: 71
Study 9670800 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐exposure in vivo with cognitive therapy
Number of subjects: 71
Study 9670800 — intervention group
Group type: COMPARATOR
Intervention: waiting‐list control group
Number of subjects: 71
Study 8110552 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-oxygen
Number of subjects: 139
Study 8110552 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen
Number of subjects: 139
Study 3198362 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mmol Gd-DTPA/kg body weight
Number of subjects: 12
Study 3198362 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml 0.9% saline/kg body weight (control)
Number of subjects: 12
Study 30822414 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Epigallocatechin-3-Gallate (EGCG)
Number of subjects: 62
Study 30822414 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Epigallocatechin-3-Gallate (EGCG) by zonal priming
Number of subjects: 62
Study 28263374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse‐led multidomain intervention targeting cardiovascular risk factors to prevent dementia
Number of subjects: 2994
Study 28263374 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2994
Study 26328470 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (162 mg/d from onion skin extract)
Number of subjects: 70
Study 26328470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 23684680 — intervention group
Group type: EXPERIMENTAL
Intervention: TV-in-TV
Number of subjects: 2554
Study 23684680 — intervention group
Group type: EXPERIMENTAL
Intervention: TVE
Number of subjects: 2554
Study 24363694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 micrograms every 4 hours, up to 6 doses)
Number of subjects: 108
Study 24363694 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter (18 F, inflated with 50 cc of sterile water)
Number of subjects: 108
Study 19692661 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (8 x 5 leg extension, 80% 1-RM) followed by repeated sprints (10 x 6 s, 0.75 Nxm torque/kg)
Number of subjects: 6
Study 19692661 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated sprints followed by resistance exercise
Number of subjects: 6
Study 19692661 — intervention group
Group type: COMPARATOR
Intervention: Both exercise orders
Number of subjects: 6
Study 19692661 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise followed by repeated sprints
Number of subjects: 6
Study 20425365 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone)
Number of subjects: 0
Study 20425365 — intervention group
Group type: COMPARATOR
Intervention: ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 0
Study 14687097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie held at 20 cm from the tip
Number of subjects: 50
Study 14687097 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie held at 30 cm from the tip
Number of subjects: 50
Study 14687097 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use bougie
Number of subjects: 50
Study 14687097 — intervention group
Group type: COMPARATOR
Intervention: Multiple-use bougie
Number of subjects: 50
Study 11761469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 8
Study 11761469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9141933 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural lidocaine
Number of subjects: 8
Study 9141933 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural saline
Number of subjects: 8
Study 8405525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal-Lys (25 micrograms/kg)
Number of subjects: 7
Study 8405525 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal-Lys (50 micrograms/kg)
Number of subjects: 7
Study 8405525 — intervention group
Group type: COMPARATOR
Intervention: Nal-Lys (0 micrograms/kg)
Number of subjects: 7
Study 3769897 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (3 mg kg‐1)
Number of subjects: 30
Study 3769897 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (1 mg kg‐1)
Number of subjects: 30
Study 3769897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30403006 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized automated clinic blood pressure measurements
Number of subjects: 0
Study 30403006 — intervention group
Group type: COMPARATOR
Intervention: Bundled standardization intervention
Number of subjects: 0
Study 26927909 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 455
Study 26927909 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control)
Number of subjects: 455
Study 23886411 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolyzed casein (hCAS) protein meal
Number of subjects: 12